China’s NMPA accepts Innovent application for sintilimab combo
Innovent Biologics has received acceptance from China's NMPA to review its sintilimab and GC101 combination for advanced melanoma.
Innovent Biologics has received acceptance from China's NMPA to review its sintilimab and GC101 combination for advanced melanoma.